Focal Segmental Glomerulosclerosis (FSGS) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - ResearchAndMarkets.com

DUBLIN--()--The "Focal Segmental Glomerulosclerosis (FSGS) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

Focal Segmental Glomerulosclerosis (FSGS) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.

Focal Segmental Glomerulosclerosis (FSGS) Analysis report covers 15 drugs currently in different phases of development. FSGS causes the formation of scar tissue in the glomerulus of the kidney. Glomerulus serves as the filtering unit of the kidney. The disease is characterised by asymptomatic proteinuria or nephrotic syndrome with or without renal insufficiency and is the most common cause of primary glomerular diseases. Symptoms of the disease are generalized edema, massive proteinuria, weight gain and poor appetite. Diagnoses is done by kidney biopsy, kidney function test and urinalysis.

The report provides Focal Segmental Glomerulosclerosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Companies Mentioned

  • Astellas Pharma Inc
  • Aurinia Pharmaceuticals Inc
  • Bristol-Myers Squibb
  • ChemoCentryx, Inc.
  • Complexa
  • Dimerix
  • Goldfinch Biopharma Inc.
  • GlaxoSmith Kline
  • Kyowa Hakko Kirin
  • Ligand Pharmaceuticals
  • Oraxion Therapeutics
  • Pfizer
  • Reata Pharmaceuticals, Inc.
  • Retrophin, Inc.
  • Silver Creek Pharmaceuticals, Inc.
  • TRISAQ Inc.
  • Variant Pharmaceuticals, Inc.
  • Vifor Pharma

Key Topics Covered:

1. Introduction

2. Disease Overview

3. Executive Summary

4. Market Dynamics

5. Pipeline Analysis/Outlook

6. Company profiling

For more information about this report visit https://www.researchandmarkets.com/research/8f5c3f/focal_segmental?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Liver and Kidney Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Liver and Kidney Disorders Drugs